Clinical trials: Oropharyngeal Cancer
Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Oropharynx (OPX) Biomarker Trial
The purpose of this research is to identify a biomarker that is exists when human papillomavirus (HPV) mediated oropharyngeal squamous cell carcinoma is present and does not exist when HPV mediated oropharyngeal squamous cell…
- Conditions
- Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Oropharyngeal Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma
- Trial name
- NCT06356272
- Testing
- Non-Interventional Study
- Where
- United States
- Volunteers
- 560 people
- Sponsor
- Mayo Clinic
Head and Neck Squamous Cell Carcinoma
Role of Microbiome as a Biomarkers in Locoregionally-Advanced Oropharyngeal Squamous Cell Carcinoma 2
This is a single-centre feasibility study designed to assess the safety, tolerability and engraftment of MET-4 bacterial strains when given in combination with chemoradiotherapy (CRT).
- Trial name
- ROMA LA-OPSCC2 (NCT03838601)
- Testing
- MET-4
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- University Health Network, Toronto
Adult Giant Cell Glioblastoma, Adult Glioblastoma
18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy
The purpose of the study is to conduct research of a new PET radiopharmaceutical in cancer patients. The uptake of the novel radiopharmaceutical 18F-FPPRGD2 will be assessed in study participants with glioblastoma multiforme…
- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Male Breast Cancer
- Trial name
- NCT01806675
- Testing
- 18F-fludeoxyglucose (18F-FDG), 18F-FPPRGD2
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Sanjiv Sam Gambhir
Oropharynx Squamous Cell Carcinoma, Oropharynx Cancer
Circulating Biomarkers in Oropharyngeal Cancers
The goal of this observational longitudinal study is to learn about circulating tumor Human Papilloma Virus-DNA (ctHPV-DNA) as a biomarker for HPV positive oropharyngeal cancer and cancer of unknown primary of the head and neck.
- Conditions
- Oropharynx Squamous Cell Carcinoma, Oropharynx Cancer, Tonsillar Cancer, Base of the Tongue Carcinoma
- Trial name
- CIRCOS (NCT05904327)
- Where
- Sweden
- Volunteers
- 130 people
- Sponsor
- Region Örebro County
Oropharynx Cancer, Larynx Cancer
Lymphocyte-Sparing And Radio-Immunotherapy in Head and Neck Carcinoma
The aim of this study is to investigate the effect of ATRA (Vesanoid) and the effect of tailored radiotherapy in patients with squamous cell carcinoma of the oropharynx, larynx or hypopharynx.
- Conditions
- Oropharynx Cancer, Larynx Cancer, Hypopharynx Cancer, Primary Head and Neck Tumor
- Trial name
- LYSARI (NCT06706401)
- Testing
- Vesanoid, Standard radiotherapy, Tailored radiotherapy
- Where
- 8 sites in France
- Volunteers
- 460 people
- Sponsor
- Centre Leon Berard
Head and Neck Cancer, Precancerous Condition
Induction Chemotherapy Followed By Cetuximab and Radiation in HPV-Associated Resectable Stage III/IV Oropharynx Cancer
RATIONALE: Drugs used in chemotherapy, such as paclitaxel and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT01084083
- Testing
- cetuximab, intensity-modulated radiation therapy (IMRT), Paclitaxel
- Where
- 121 sites in United States
- Volunteers
- 90 people
- Sponsor
- Eastern Cooperative Oncology Group
Head and Neck Cancer
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00006051
- Testing
- cisplatin, fluorouracil, radiation therapy
- Where
- 6 sites in France
- Sponsor
- UNICANCER
Paranasal Sinus Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma
Capecitabine and Vorinostat in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer
This partially randomized phase II trial studies giving capecitabine and vorinostat in treating patients with head and neck cancer that has come back after previous treatment or that has spread to other areas in the body.
- Conditions
- Paranasal Sinus Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Oral Cavity Squamous Cell Carcinoma
- Trial name
- NCT01267240
- Testing
- Capecitabine, Vorinostat
- Where
- 14 sites in United States, Canada
- Volunteers
- 25 people
- Sponsor
- National Cancer Institute (NCI)
Head and Neck Carcinoma
Predicting Radiological Extranodal Extension in Oropharyngeal Carcinoma Patients Using AI
Development and validation of a model that predicts rENE from radiological imaging using annotated / labeled scans by means of deep learning
- Trial name
- AI4rENE (NCT05565313)
- Where
- 3 sites in United States, Canada and 1 more
- Volunteers
- 900 people
- Sponsor
- Maastricht Radiation Oncology
Cranial Nerve Injury, Oropharyngeal Cancer
Proactively Intervening On Early Cranial Nerve Injury As A Delayed Sequela Of Oropharyngeal Cancer: A Randomized Feasibility Clinical Trial For Pro-Habilitation (proNERVE RCT)
The goal of this clinical research study is to learn about possible intervention strategies to help control cranial neuropathy in patients after they receive radiation therapy for OPC.
- Trial name
- NCT07832266
- Testing
- Prednisone, Ajovy, Manual Therapy
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- M.D. Anderson Cancer Center
Head and Neck Cancer, Oral Complications
Pilocarpine in Preventing Mucositis and Dry Mouth in Patients Receiving Radiation Therapy for Head and Neck Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs such as pilocarpine may protect normal cells from the side effects of radiation therapy.
- Trial name
- NCT00003139
- Testing
- pilocarpine hydrochloride
- Where
- 232 sites in United States, Canada
- Volunteers
- 249 people
- Sponsor
- Radiation Therapy Oncology Group
Primary Snore, Obstructive Sleep Apnea (Mild and Moderate).
Effects of Oropharyngeal Exercises on Patients With Primary Snore, Mild and Moderate Obstructive
Randomized study of patients with primary snore, mild and moderate obstructive sleep apnea. Protocol include 40 patients randomized to oropharyngeal exercise or use of nasal dilator, breathing exercise and nasal lavage.
- Trial name
- EOE (NCT01636856)
- Testing
- Oropharyngeal exercises, Respiratory exercises, nasal dilator, nasal lavage
- Where
- Brazil
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of Sao Paulo
Head and Neck Cancer, Oropharyngeal Cancer
Reflux Disease in Head and Neck Cancer Patients Undergoing Radiation Therapy
The goal of this clinical research study is to learn if radiation-induced xerostomia [RIX] (dry mouth) causes, or worsens the effects of, acid reflux (heartburn and heartburn-like symptoms) in head and neck cancer (HNC) patients…
- Conditions
- Head and Neck Cancer, Oropharyngeal Cancer, Gastroesophageal Reflux Disease
- Trial name
- NCT00928161
- Testing
- Dexlansoprazole
- Sponsor
- M.D. Anderson Cancer Center
Oropharynx Cancer, HPV-Related Carcinoma
Trial of Individualized Adaptive RT in HPV-related High Risk Oropharynx Cancer
This study seeks to study the population of HPV-related oropharynx cancer patients that appear to be at highest risk for treatment failure with loco-regional failure and distant metastases including cT4 or cN3.
- Trial name
- ARTHOUSE (NCT06234748)
- Testing
- Radiation, Platinum based chemotherapy
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of Michigan Rogel Cancer Center
Oropharyngeal Squamous Cell Carcinoma
Lattice-Based Radiotherapy and Chemoimmunotherapy for Oropharyngeal Squamous Cell Carcinoma
This single-arm Phase I/II trial evaluates induction chemoimmunotherapy combined with lattice radiotherapy (LRT) in patients with non-low risk oropharyngeal squamous cell carcinoma and primary tumor ≥3 cm or primary tumor and…
- Trial name
- NCT07428148
- Testing
- Induction Chemo-Immunotherapy, Lattice Radiotherapy
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- NYU Langone Health
Oropharynx Cancer
Adaptative Radiotherapy to Decrease Xerostomia in Oropharynx Carcinoma
The Phase III study will include 174 patients with locally advanced oropharynx carcinoma, receiving all arc-IMRT (Intensity-Modulated Radiation Therapy) (70 Gy) with concomitant systemic therapy.
- Trial name
- ARTIX (NCT01874587)
- Testing
- adaptative radiotherapy
- Where
- 11 sites in France
- Volunteers
- 132 people
- Sponsor
- Center Eugene Marquis
Head and Neck Neoplasms
Definitive Chemo-Radiotherapy for Regionally Advanced Head and Neck Cancer With or Without Up-front Neck Dissection
Treatment of regionally-advanced head and neck squamous cell carcinoma (HNSCC) requires a multidisciplinary approach with a combination of surgery, radiotherapy (RT) and chemotherapy.
- Trial name
- UPFRONT-NECK (NCT02918955)
- Testing
- up-front neck dissection, radiotherapy, Chemotherapy (Cisplatin)
- Where
- 2 sites in Switzerland
- Volunteers
- 65 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
HPV Positive Oropharyngeal Squamous Cell Carcinoma, Oropharynx Cancer
Therapy for High-Risk HPV 16-Positive Oropharynx Cancer Patients
Combination immune checkpoint inhibitor and DNA vaccine will result in clearance of HPV DNA biomarkers (oral and/or plasma) for patients with persistent HPV-16 E6/E7 DNA (HPV biomarker) after treatment with curative intent.
- Conditions
- HPV Positive Oropharyngeal Squamous Cell Carcinoma, Oropharynx Cancer, HPV-Related Carcinoma
- Trial name
- NCT04001413
- Testing
- MEDI0457, Durvalumab
- Where
- 4 sites in United States
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
HPV Positive Cancer, Vulvar, Vaginal, Penile, Rectal Cancer
HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated Cancers
Background: For some cancers associated with human papillomavirus (HPV), standard treatments are not helpful. Researchers want to see if a vaccine for HPV combined with a drug called M7824 (MSB0011359C) has a better effect on…
- Conditions
- HPV Positive Cancer, Vulvar, Vaginal, Penile, Rectal Cancer, Anal Cancer, Oropharyngeal Cancer
- Trial name
- NCT04432597
- Testing
- PRGN-2009, M7824, EKG
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- National Cancer Institute (NCI)
Head and Neck Cancer
Contact Allergies to Dental Metal as a Possible Risk Factor for Oral Cancer
RATIONALE: Gathering information about allergies to metals may help doctors learn whether having an allergy to metal used in dental work increases the risk of developing oral cancer.
- Trial name
- NCT00693550
- Testing
- metal patch tests
- Where
- United States
- Volunteers
- 115 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic